Recent GLYC News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 09:47:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:42:19 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/06/2024 10:41:38 PM
- GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting • Business Wire • 11/06/2024 12:00:00 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 11/04/2024 09:26:15 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/04/2024 07:01:21 PM
- Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement • AllPennyStocks.com • 10/29/2024 02:00:00 PM
- Biotech Up Over +100% Premarket Following Merger And Funding Announcement • AllPennyStocks.com • 10/29/2024 02:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/29/2024 12:09:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 12:09:13 PM
- GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma • Business Wire • 10/29/2024 11:00:00 AM
- GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint • Business Wire • 10/29/2024 10:30:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/15/2024 09:01:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 07:55:22 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/29/2024 11:24:49 PM
- GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan • Business Wire • 07/25/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 01:30:15 PM
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 06/04/2024 11:00:00 AM
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 • Business Wire • 05/29/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:01:01 PM
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 05/06/2024 10:00:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM